Immunologic Factor
Merus’ Bispecific Antibody Therapy Shows Promising Early Results in Cancer Treatment
Merus, bispecific antibody, cancer treatment, early results, investor expectations, ASCO
Tremfya Emerges as a Promising Successor to Stelara in J&J’s Pipeline with Robust Clinical Data
J&J, Tremfya, Stelara, successor, head-to-head data, clinical trials, psoriasis treatment, biologics.
AltruBio Secures $225 Million for Phase II Trials of Novel Immune Checkpoint Enhancing Antibody
AltruBio, funding, Phase II trials, immune checkpoint enhancing antibody, cancer treatment, immunotherapy, biotechnology, healthcare innovation.
Tremfya Phase III Maintenance Study Results Presented by J&J for Ulcerative Colitis Treatment
J&J, Johnson & Johnson, Tremfya, guselkumab, Phase III trial, maintenance study, ulcerative colitis, inflammatory bowel disease, treatment, efficacy, safety, remission.
Moderna Secures Victory in EU Patent Dispute with Pfizer-BioNTech over COVID-19 Vaccine
Moderna, Pfizer, BioNTech, EU, patent dispute, COVID-19 vaccine, mRNA technology, European Patent Office (EPO), intellectual property rights, pharmaceutical industry.
WHO Approval for Takeda’s Dengue Vaccine: A Breakthrough in Global Health
WHO, Takeda, dengue vaccine, prequalification, global health, regulatory tracker, breakthrough, approval.
Pharmaceutical Giants Sanofi, Pfizer, and AstraZeneca Pump $1.87 Billion into French Operations
Sanofi, Pfizer, AstraZeneca, France, investment, pharmaceutical industry, operations, vaccine production, research and development, manufacturing.
AstraZeneca’s COVID-19 Antibody Treatment Shows Promising Results in Immunocompromised Individuals
AstraZeneca, COVID-19, antibody treatment, immunocompromised individuals, enhanced protection, clinical trials, monoclonal antibodies, virus neutralization, immune response.
AstraZeneca’s Next-Generation Covid Therapy Shines in Phase 3 Trials
AstraZeneca, Covid-19, Evusheld, Phase 3 trials, next-generation therapy, successor, antibody treatment, prevention, efficacy, safety.
Johnson & Johnson Expands into IL-13 and TSLP Market with Strategic Acquisition
Johnson & Johnson, I&I acquisition, IL-13, TSLP, competitive market, strategic expansion, pharmaceutical industry, biologics, inflammatory diseases.